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Abstract: Whether the gut microbiome in obesity is characterized by lower diversity and altered
composition at the phylum or genus level may be more accurately investigated using high-throughput
sequencing technologies. We conducted a systematic review in PubMed and Embase including
32 cross-sectional studies assessing the gut microbiome composition by high-throughput sequencing
in obese and non-obese adults. A significantly lower alpha diversity (Shannon index) in obese
versus non-obese adults was observed in nine out of 22 studies, and meta-analysis of seven studies
revealed a non-significant mean difference (−0.06, 95% CI −0.24, 0.12, I2 = 81%). At the phylum level,
significantly more Firmicutes and fewer Bacteroidetes in obese versus non-obese adults were observed
in six out of seventeen, and in four out of eighteen studies, respectively. Meta-analyses of six studies
revealed significantly higher Firmicutes (5.50, 95% 0.27, 10.73, I2 = 81%) and non-significantly lower
Bacteroidetes (−4.79, 95% CI −10.77, 1.20, I2 = 86%). At the genus level, lower relative proportions of
Bifidobacterium and Eggerthella and higher Acidaminococcus, Anaerococcus, Catenibacterium, Dialister,
Dorea, Escherichia-Shigella, Eubacterium, Fusobacterium, Megasphera, Prevotella, Roseburia, Streptococcus,
and Sutterella were found in obese versus non-obese adults. Although a proportion of studies found
lower diversity and differences in gut microbiome composition in obese versus non-obese adults, the
observed heterogeneity across studies precludes clear answers.
Keywords: gastrointestinal microbiome; adult; humans; obesity; BMI; 16S sequencing; shotgun
metagenomics
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1. Introduction
Obesity is a major public health problem worldwide [1]. In the year 2016, the global
prevalence of overweight in adults (defined as body mass index, BMI ≥ 25 kg/m2) was
39% (1.9 billion adults), and the prevalence of obesity in adults (BMI ≥ 30 kg/m2) was 13%
(650 million adults) [1]. It was estimated that by 2030, 2.16 billion (38%) individuals of the
world’s adult population will be overweight and 1.12 billion (20%) will be obese [2]. Obesity
is a risk factor for major chronic diseases, such as cardiovascular diseases [3], various types
of cancer [4,5], and for premature death [6]. Obesity is the consequence of a positive energy
balance resulting from the interaction of genetic and non-genetic factors, including personal,
environmental, and nutritional factors [7]. There is evidence from animal studies that the
gut microbiome may also play a role in the development of obesity [8,9]. Furthermore, some
studies in humans suggest that the microbiome composition may differ between obese and
non-obese persons, and it was speculated whether such differences may contribute to the
higher disease risk observed in obese persons, but findings have been inconsistent [10].
The human gut microbiome is composed of two dominant phyla, Firmicutes and Bac-
teroidetes, accounting for 90% of the total community, as well as the phyla Proteobacteria,
Actinobacteria, and Verrucomicrobia, which are less dominant [11]. Among the 200 dif-
ferent genera belonging to the Firmicutes phylum are Lactobacillus, Bacillus, Clostridium,
Enterococcus and Ruminococcus, whereas the most predominant genera belonging to the
Bacteroidetes phylum are Bacteroides and Prevotella [11], although taxonomic classifica-
tions depend on the reference database used [12]. Animal studies found that when gut
microbiota from conventionally raised wild-type mice was transplanted into germ-free
mice, a rapid increase in their body fat by 60% was observed without changing their food
consumption [13], and when gut microbiota from obese adult female humans were trans-
planted to germ-free mice, a rapid increase in their body weight was also observed [14].
Another study showed that the gut microbiota of genetically obese mice (ob/ob) was
less diverse compared to their lean counterparts, and was also found to be enriched in
Firmicutes and depleted in Bacteroidetes [15]. In humans, findings have been inconsistent,
with some studies finding a higher relative abundance of the Firmicutes as compared to
the Bacteroidetes phyla (often also expressed as ratio) in obese as compared to non-obese
persons, whereas others found no such associations [9,16–21]. Differences in the study
population (e.g., age, sex, geographic region) or specific health-related subgroups (e.g.,
metabolic status in obese persons) could explain the high inter-individual variation in the
gut microbial community of the gut microbiota [8], which precludes the definition of a
reference microbiome in health and disease [22]. In addition, differences in microbiome
measurement techniques and annotation are likely to have contributed to the heterogeneity
of findings in the past [23].
Two systematic reviews exploring the differences in the gut microbiome composition
between obese and non-obese mixing adults and children [24] or in adults only [25] have
previously been conducted, although none conducted meta-analysis. Both these systematic
reviews and other non-systematic reviews [26–28] tried to answer whether obesity is asso-
ciated with a higher or lower gut microbiome diversity compared to lean individuals and
also whether the Firmicutes to Bacteroidetes (F:B) ratio can be considered a relevant marker
of gut dysbiosis in obese persons. The systematic reviews in adults from observational and
intervention studies (bariatric surgery patients) [24,25] concluded that obese persons have
different profiles of gut microbiota compared to the non-obese. Higher relative abundance
of the phyla Firmicutes, Proteobacteria, and Fusobacteria, as well as the genus Lactobacillus
were found in obese compared with lean individuals, whereas the phylum Bacteroidetes, as
well as the species Faecalibacterium prausnitzii, Akkermansia muciniphila, Methanobrevibacter
smithii, and Bifidobacterium animalis were found in lower relative abundance in the obese
compared to the lean [25]. However, inconsistent results were found in the diversity of
the gut microbiota associated with obesity [25]. Both systematic reviews attributed such
inconsistent results to technical factors, such as the inclusion of studies that used different
methodologies for the quantification of microorganisms [24,25]. Other technical factors that
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may contribute to divergent results are: different sequencing techniques for microbiome
quantification, differences in the primers used and methods for DNA extraction, as well
as the reference database used for the classification [23,25,29]. However, none of these
systematic reviews addressed the issue of the lack of definition of criteria to select the
appropriate reference database for taxonomic classification. Non-technical factors that
have been shown to have an impact on the gut microbial composition, but are in available
studies rarely or insufficiently controlled for include sex, season, dietary patterns, exercise,
medication, and geographical aspects [25]. Both systematic reviews make a plea for future
studies quantifying the gut microbiome using high-throughput sequencing techniques
(so-called next generation sequencing technologies) to disentangle the complexity of the
gut microbiome.
This is the first systematic review with meta-analysis addressing differences in the
gut microbiome composition in obese versus non-obese adults focusing on studies using
high-throughput sequencing technologies (e.g., 16S rDNA/rRNA sequencing, shotgun
metagenomics). Our primary aim was to assess differences in the gut microbiome compo-
sition and diversity (alpha and beta-diversity) at the phylum and genus levels between
obese and non-obese adult individuals from the general population based on data from
observational studies. Further, we aimed to test the hypothesis that obese as compared to
non-obese persons have a higher F:B ratio, which could be considered a hallmark of the
pathophysiology of obesity. We also describe microbial taxonomic signatures associated
with obesity reported by the included studies.
2. Materials and Methods
2.1. Data Sources and Search Strategy
This systematic review is reported in accordance with the recommendations set forth
by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement [30]. The protocol was prospectively registered at PROSPERO (CRD42021225730).
A systematic search was conducted in November 2020 using computerized bibliographic
databases, such as PubMed and EMBASE via Ovid from inception to 19 November 2020.
The search included a combination of MeSH terms and free text to retrieve articles on
obesity, including anthropometric measurements, and gut microbiome, and was restricted
to English language (see Supplement Table S1 for the search strategy).
We obtained further references from the reference list of the studies included in the
qualitative synthesis. Search results were imported from PubMed and EMBASE XML
into the CAMARADES Preclinical Systematic Review & Meta-analysis Facility (SyRF)
(https://app.syrf.org.uk/ (last accessed on 5 March 2021)) for title and abstract screening as
well as for full text assessment. To manage the references, we used EndNote X7® (Thomson
Reuters) software.
2.2. Exposures and Comparators
Obesity was the primary exposure of interest. Obesity was defined by body mass
index (BMI) ≥ 30 kg/m2 as compared to non-obesity (BMI < 30 kg/m2). Secondary
exposures were: (1) abdominal obesity based on waist circumference ≥102 cm in men and
≥88 cm in women, or waist-to-hip ratio ≥0.95 in men and ≥0.80 in women as compared to
non-obesity based on waist circumference <102 cm in men and <88 cm in women, or waist-
to-hip ratio <0.95 in men and <0.80 in women; (2) overweight individuals were defined
by BMI ≥ 25 kg/m2 as compared to non-overweight (BMI < 25 kg/m2). Alternative BMI-
based obesity definitions, e.g., for Asian populations, were also considered.
2.3. Outcome Measures
The primary outcomes of interest were: (1) differences in the alpha and beta-diversity
between obese and non-obese persons; (2) differences in the Firmicutes to Bacteroidetes ratio
between obese and non-obese persons; and (3) differences in gut microbiome composition
between obese and non-obese persons.
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Microbial diversity can be expressed as the number of distinct species in a community
(richness), the even distribution of their abundances (evenness) or a combination of both
aspects, commonly termed alpha diversity. Microbial alpha diversity is estimated using the
Shannon and Simpson indices, whereas microbial richness is estimated using the Chao1
index, or number of observed species/operational taxonomic units (OTUs).
The secondary outcome of interest was to describe microbial taxonomic signatures
associated with obesity.
2.4. Inclusion and Exclusion Criteria
Inclusion criteria were human observational studies comparing the composition of
the gut microbiome between obese and non-obese adult individuals (age ≥ 18 years)
recruited from the general population, irrespective of ethnicity. If studies included a
mixed population of children and adults, only those studies presenting their data for
adults separately were included. A further inclusion criterion was that the gut microbiome
was measured by means of high-throughput analyses (e.g., 16S rDNA/rRNA sequencing,
shotgun metagenomics) in fecal samples.
Exclusion criteria were intervention studies and randomized controlled trials. Further
exclusion criteria were: (1) no report of data on obese and non-obese persons, or (2) gut
microbiome measured in samples other than feces or by means of culture-dependent
techniques or other non-high-throughput sequencing techniques, or (3) in adults that have
undergone different types of bariatric surgery. Studies focusing on specific diseases, written
in a language other than English, or published as abstract, editorial or comment were
also excluded.
Systematic and narrative reviews were kept for background only and their data were
not extracted.
2.5. Study Selection and Data Extraction
Two researchers (MP and KN) independently screened the titles and abstracts, and
reviewed the full texts. Disagreements were resolved through discussion and consensus, or
if necessary, with referral to a third researcher (TP). The same investigators designed and
piloted a data extraction form before routine use, and extracted the data independently.
When needed, the primary study author was contacted to obtain further information. For
each included study the following information was extracted: study ID (first author and
year of publication), country, study design, study population, sample size, definition of
obesity, overweight and non-obesity, method used to measure microbiome, DNA extraction
method, platform used, outcomes assessed, results on composition and diversity of gut
microbiome in obese versus non-obese and/or differences in comparison groups, and
characterization of microbiome taxonomic signatures in obese persons. We also selected
relevant titles from the reference lists of those studies that were finally included for qualita-
tive synthesis, obtained their abstract and followed the same procedure as above described
to identify further studies.
2.6. Quality Assessment
Two independent researchers (MP and KN) appraised the risk of bias using an adapted
version of the Risk Of Bias In Non-Randomized Studies of Interventions (ROBINS-I)
tool [31], a tool proposed by Cochrane that can be also applied to appraise the risk of
bias in observational studies. Discrepancies were resolved by discussion and consultation
with a third author where necessary. The adapted version of ROBINS-I tool comprised
six domains of bias due to: (1) confounding, (2) selection of participants, (3) exposure
assessment, (4) missing data, (5) measurement of the outcome, and (6) selective reporting of
the results, together with the signaling questions that facilitated the judgement of potential
risk of bias for each domain as described in Supplement Table S2. The overall judgment
of risk of bias was categorized as low, moderate or serious as previously described [31].
If at least one domain was judged to be of serious risk but not at critical risk in any other
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domain, then the overall judgment of the risk of bias was deemed as serious. If all domains
were rated as being at low risk of bias, then the overall judgment was deemed as low. If
all domains were rated at low or moderate risk of bias, then the overall judgement was
deemed as moderate.
2.7. Data Synthesis
For the data synthesis studies that presented results separately for different subpopula-
tions defined by sex [32,33] or geographic region [34,35] were counted as separate studies.
For a qualitative data synthesis, we counted the number of studies addressing each
outcome that showed significantly higher or lower or non-significant differences for the
respective outcome in obese versus non-obese adults as reported by the studies and/or
based on nominal p-values (p < 0.05 considered statistically significant).
For the quantitative data synthesis, we used the extracted study-specific means and
nominal p-values or the mean difference (MD) between obese and non-obese adults with
95% confidence intervals (CIs) to combine multiple studies that measured the same contin-
uous outcome using similar methods and the same unit of measurement. We also extracted
the means and standard deviation (SD) to calculate the MD 95% CIs for the meta-analysis. If
standard deviation data were not available, it was calculated based on p values or standard
errors, if possible (https://training.cochrane.org/resource/revman-calculator (accessed on
27 July 2021)). Because we anticipated substantial between-study heterogeneity, a random-
effects model was applied to obtain pooled effect size estimates, 95% CIs and p-values
through the inverse variance method and restricted maximum-likelihood estimator [36].
Statistical heterogeneity was determined by the I2 statistic, and it was regarded as sub-
stantial if I2 was found to be between 40% and 70%. A sensitivity analysis was performed
when estimates revealed heterogeneity >70% by removing one study at a time, and the
study driving the heterogeneity was excluded from the meta-analysis. Because fewer than
10 studies for each outcome qualified for meta-analyses, publication bias was not inspected.
The “meta” (Version 4.18-0) and “metaphor” (Version 2.4-0) packages were used to perform
meta-analyses in R and statistical significance was determined at the p < 0.05 level.
3. Results
3.1. Search Flow and Studies Overview
The detailed output of the searches and the process followed for the identification is
displayed in the PRISMA flowchart (Figure 1). From a total of 2445 unique hits, 116 stud-
ies were selected for full-text review. Of these, 33 primary reports [17–21,32–35,37–60],
including 32 studies met the criteria for inclusion and were selected for data extraction
and synthesis.
Table 1 describes the characteristics of the included studies, which were of cross-
sectional design and were published between 2012 and 2020, yielding 13,186 individual
stool samples for microbiome analyses. All studies included both males and females with
the exception of two studies [19,34] that included females only and one study [35] that
included males only. Ten studies were from North and South America (Canada, n = 1; Mex-
ico, n = 1; USA, n = 6; Brazil, n = 1; Colombia, n = 1), nine were from Asia-Pacific countries
(Australia, n = 1; Bangladesh, n = 1; China, n = 1; India, n = 1; Japan, n = 3; Korea, n = 1;
Saudi Arabia, n = 1), seven from Europe (Finland, n = 2; Germany, n = 1; Italy, n = 2; Nether-
lands, n = 1; UK, n = 1), two from Africa (Egypt, n = 1; South Africa, n = 1), and four were
conducted in multiple countries (Table 1). Two studies also assessed the fungal composition
and diversity of the human gut microbiota in obese and non-obese adults [38,48]. The region
of amplification of the 16S rRNA gene varied across studies, such as such V3–V4 (n = 11),
V4 (n = 9), V3–V5 (n = 2), V3 (n = 1), V1–V2 (n = 1), V1–V3 (n = 1), V1–V4 (n = 1), and V6
(n = 1). Three studies [18,56,59] did not specify the amplified region of the 16S rRNA gene
(Figure 2). To explore the fungal composition and diversity of the gut microbiota, one study
amplified the fungal 18S rRNA gene (region V7–V8) with fungal primers [38], and another
study amplified the ITS1 fragment [48]. The most widely used sequencing platform was the
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Illumina MiSeq (n = 23). Shotgun metagenomics was conducted in three studies that used
BaseSpace through the 16S Metagenomics app from Illumina® [45], Illumina HiSeq [55],
and the Ion-Proton sequencing platforms [57]. Two studies used high-throughput meth-
ods that are not considered as next-generation sequencing, but are the microarray-based
HITChip method [56] and parallel Sanger sequencing of cloned amplicons of the 16S rRNA
gene [52]. The database in which taxonomic binning of 16S reads were based on was not
reported in three studies [32,40,53]. The rest of the studies mainly used the Greengenes
database (n = 17) [18,19,37,39,41,43–46,48,50,51,54,58–60], RDP (n = 4) [20,34,52,55], SILVA
(n = 3) [35,47,54], NCBI (n = 2) [38,57], or DB-BA9.0 (n = 2) [17,21]. Other databases used
were: Broad Institute Microbiome Utilities microbiomeutil-r20110519 database [33], KEGG
(Kyoto Encyclopedia of Genes and Genomes) Orthology (KO) Database at level 2 and level
3 [54], HUMAnN2 v0.11.1 [55] for shotgun metagenomics, and UNITE reference database
for fungal taxonomy [48] (Figure 2). One study did not use a publicly available database
but a HITChip specific database [56].
Figure 1. Description of the selection of the included studies following a PRISMA flow diagram.
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MOBIO PowerSoil DNA

































Project launched in 2005 an
annual health check-up for
local residents living in the
Iwaki region of Hirosaki City,
Aomori Prefecture. Data
obtained from the 2015 health
checkup and a confirmation
group from the 2016 health
check (not in the 2015 one)
1001
(391 ♂, 610 ♀; mean age ± SD:
51.2 ± 14.1 y ♂, 54.2 ± 13.7 y
♀). Confirmation group: 326
(62% ♀, mean age
50.7 ± 17.5 y)
O: BMI ≥ 30 kg/m2
OW: 25 ≤ BMI <
30 kg/m2
NW: 20 ≤ BMI <
25 kg/m2
UW: BMI < 20 kg/m2
4 groups: VFA 28 < 50,
50 ≤ VFA < 100, 100 ≤
VFA 28 < 150,
VFA 28 ≥ 150
Collected using a
commercial tube kit and
cotton swabs within
3 days prior to the study,






MagDEA DNA 200 (GC)
reagent kit (Precision









Indian origin (21–62 years
old) irrespective of gender
20 (5 individuals/group)
Median age in years:
L (age: 23 y),
NW (age: 44 y),
O (age: 45 y),
O (treated) (age: 50 y)
O: 25–53 kg/m2, n = 5,
O (treated):
25–36 kg/m2, regressing
to normal BMI after SG
29 and AGB 30 surgeries.
NW: 18–24 kg/m2, n = 5,
L: BMI < 19 kg/m2, n = 5
Collected from unrelated
healthy individuals.
Stored at 4 ◦C and
transported to laboratory
on ice, and processed
immediately or stored at
−80 ◦C
QIAamp DNA Stool
Mini Kit (Qiagen) with
an additional step of
bead beating using a mix











colonoscopy clinics: the CDC
14 study, and the NYU 15
study. Predominantly white
(94%)
599 (423 from CDU and
176 from NY study)
Aged (62 ± 7 y)
O: BMI ≥ 30 kg/m2
OW: 25.0 ≤ BMI <
30.0 kg/m2




cards at home. Mailed to
a laboratory for fecal
occult blood testing.
Samples refrigerated at
4 ◦C, and stored at
−80 ◦C
PowerLyzer PowerSoil

















17 years recruited via
advertisements (University
of Toronto campus) and from
a pool of subjects previously
involved in studies by
their group
22
L (35.8± 4.2 y);
OW (42.5 ± 3.9 y)
OW: BMI > 25
L: BMI ≤ 25




full of dry ice kept at
−20 ◦C
DNA extraction method































Adult patients with obesity
and diabetes in a population
sample from El-Sharkia
governate in North East
Egypt
60; age (43.95 ± 13.35 y),
gender (31 ♂, 29 ♀); 5 (C),
25 (O), 5 (D), and 25 (OD)






SILVA SSU Ref NR
dataset v.132 (OTUs),
Greengenes (v 13.8),
KEGG 37, KO 38








PopGen 16 (n = 436) and
FoCus 17 (n = 844)
1280 (L = 633; O = 494;
OT2D = 153)
O: BMI >30 no T2D 31
OT2D: BMI >30 with
T2D 31
L: BMI < 25 no T2D 31
NR
QIAamp DNA Stool
Mini Kit from QIAGEN.
16S (V1–V2).












From May to September 2010,
adults recruited through
advertising at the Atrium
Medical Center Parkstad in
Heerlen, The Netherlands
28 Non-obese (n = 13): 9 lean
and 4 were OW. Obese
(n = 15): 9 were morbid obese.




O: BMI > 40 kg/m2
(range 40.4–60.3 kg/m2);
OW: BMI range
25.2–29.6 kg/m2; L: BMI
range 18.6–24.6 kg/m2




and stored in aliquots at
−20 ◦C
























888 (NO (n = 414) versus O
(n = 474)). Median age 54
[18–76} y; 574 ♀and 314 ♂
O: BMI ≥ 30
NO: BMI < 30
Collected according to
the IHMS 34 guidelines
(modified SOP 04 V1
(collection without
anaerobic bag)). Stored
(less than 48 h) at −20 ◦C
DNA extracted following
the IHMS guidelines








Students from a larger study
in two residence halls at
Arizona State University in
Tempe, Arizona (Fall 2014
and Spring 2015 semesters).
31.7% Hispanic; 39.0% White;
29.3% Other
82 (UW (5); NW (47); OW
(18); O (12)).
57.3% ♀; age mean ± SD;
18.4 ± 0.6 y
O: BMI ≥ 30.0 kg/m2
OW: 25.0 ≤ BMI <
30.0 kg/m2
NW: 18.5 ≤ BMI <
25.0 kg/m2
UW: BMI < 18.5 kg/m2
Collection kit in small
insulated cooler bags
containing ice packs to
be frozen immediately
for 36–48 h in an
insulated container.
Samples delivered to the
facility within 24 h of
collection, and stored at
−80 ◦C
PowerSoil DNA isolation




































American Gut Project data
(2012–2017)
600 (300 H; 300 O)
Chronic disease state: if
“diagnosed” for CVD 32,
diabetes, or KD 33, or
with “obese” for BMI.
Health status based on
self-reported medical
diagnoses. Healthy: “I
do not have this
condition” entry for
diabetes, CVD 32, and



















Volunteers from France and
SA 20 living in urban areas
France: 28 (O (12) 58%♂; NW
(16) 44%♂)
SA 20: 18 (O (9); NW (9)).
All ♂
Age mean ± SD:
NW (France): 34 ± 5 y
NW (SA 20): 28 ± 4 y
O (France): 39 ± 13 y
O (SA 20): 26 ± 3 y
O: BMI > 30 kg/m2
NW: BMI 20–25 kg/m2
Stool samples collected
under aseptic conditions
with clean, dry screw-top
containers immediately













cohort study: men and





1274 (NW (529); OW (326); O
(419)); age 45.7 (9.0) y; sex,
♂: 63.7%
Revised Asia-Pacific BMI
criteria by the WHO
Western Pacific Region:
O: BMI ≥ 25
OW: 23 ≤ BMI < 25
NW: 18.5 ≤ BMI < 23
NR
MO-BIO PowerSoil DNA






1 H: Healthy, L: Lean, NO: non-obese, NW: Normal weight, OW: Overweight, O: Obese, UW: underweight, WHO: world Health Organization; 2 ♂: males, ♀: females, MZ: monozygotic,
DZ: dizygotic, SD: standard deviation; 3 RoB: Risk of Bias; 4 M: moderate risk of bias, S: serious risk of bias; 5 TUK-D: TwinsUK Adult Twin Registry; 6 UHFJF: University Hospital–Federal
University of Juiz de Fora; 7 GOS: Geelong Osteoporosis Study; 8 METS: Modeling the Epidemiologic Transition Study; 9 HMP: Human Microbiome Project; 10 MetaHIT: METAgenomics
of the Human Intestinal Tract; 11 H3Africa: Human, Heredity and Health in Africa consortium; 12 METSIM: METabolic Syndrome In Men; 13 HEALS: Health Effects of Arsenic
Longitudinal Study; 14 CDC: the Centers for Disease Control and Prevention Study of In-home Tests for Colorectal Cancer; 15 NYU: New York University Human Microbiome and
Colorectal Tumor study; 16 PopGEN: Population Genomic Diversity of Germany; 17 FoCus: Food Chain Plus; 18 BMIS: transnational Body Mass Index spectrum cohort; 19 departments of
the Pitie-Salpetriere Hospital (Paris, France), the Integrated Research and Treatment Center for Adiposity Diseases (Leipzig, Germany), and the Novo Nordisk Foundation Center for
Basic Metabolic Research (Copenhagen, Denmark); 20 SA: Saudi Arabia; 21 VFM: visceral fat mass; 22 SFM: subcutaneous fat mass, 23 pFT: % trunk fat, 24 AGR: android/gynoid ratio;
25 WHR: waist/hip ratio; 26 FMI: fat mass index; 27 WC: waist circumference; 28 VFA: visceral fat area where VFA ≥ 100 cm2 (obesity); 29 SG; 30 AGB:; 31 T2D: type 2 Diabetes; 32 CVD:
cardiovascular diseases; 33 KD: kidney diseases; 34 IHMS: International Human Microbiome Standards guidelines; 35 NCBI: National Center for Biotechnology Information; 36 RDP:
Ribosomal Database Project; 37 KEGGS: Kyoto Encyclopedia of Genes and Genomes; 38 KO: Kyoto Orthology Database; 39 NGS: next-generation sequencing. NR: not reported.
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Figure 2. SrRNA, by amplified region, or Shotgun metagenomics; (b) reference databases used for
taxonomic classification reported in 32 studies. Note that some studies amplified multiple regions or
used multiple databases.
A total of two studies used BMI < 30 as reference [20,57], nine studies used
BMI < 25 [18,26,34,35,43,44,47,53,55], one study used BMI < 20 [21], fifteen studies used
BMI 18.5–24.9 [19,32,33,41,45,46,48,49,51,52,54,56,58–60], and one study from Japan used
BMI < 18.5 as a reference [17]. However, in general, studies from Asia used lower cut-offs
than studies from Europe to define obesity. Three other studies did not specify the BMI
cut-offs of comparison groups [9,37,38]. One study did not use the BMI but instead used
the fat mass index (FMI) [39], and two studies used both the BMI and the visceral fat area
(VFA) [32] or the waist circumference [43].
3.2. Primary Outcomes
3.2.1. Alpha and Beta Diversity (Microbial Diversity and Richness,
Microbial Dissimilarities)
Of the 32 included studies, 25 studies investigated alpha diversity in obese versus
non-obese adults, two did not assess alpha diversity, and five studies did not report alpha di-
versity stratified by BMI (Table 2). At the individual study level, results on the difference in
alpha diversity between obese and non-obese persons were discrepant (Figure 3): the Shan-
non index, reported in 22 studies, was found to be significantly lower in obese compared to
non-obese adults in nine studies [17,32,35,37,41,46,48,51,54], higher in two studies [21,54],
and not significantly different in eleven studies [19,33–35,39,44,45,47,49,52,53]. The study
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of Salah et al. [54] found significantly lower diversity (Shannon index) among obese as
compared to non-obese persons and higher diversity among obese diabetic compared to
non-obese persons. Yasir et al. [35] found significantly lower diversity (Shannon index)
among obese as compared to non-obese persons only among the French participants, but
no significant differences among the Saudi Arabian participants. In order to further explore
the role of methodological factors in microbiome measurement, we restricted the qualitative
analysis of the Shannon index (n = 22 studies in total) to studies that amplified the V3–V4
region (most commonly amplified region, n = 12 studies), studies that used the Greengenes
database (most commonly used database, n = 10 studies) as well as studies that amplified
the V3–V4 region and used Greengenes database (n = 3 studies) (Supplement Figure S1).
Restriction to studies amplifying the V3–V4 region revealed that half of the studies (six
out of twelve) observed a lower Shannon index in obese versus non-obese persons and
restriction to studies amplifying the V3–V4 region and using the Greengenes database
revealed that a fifth of the studies (two out of ten) observed a lower Shannon index in obese
versus non-obese persons (Supplement Figure S1).
Figure 3. Number of studies that reported alpha diversity indices Panel (a) or richness estimators
Panel (b) as significantly higher (grey), lower (diagonal stripes) or not different (dotted) when
comparing obese to non-obese persons.
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Groups 1 Alpha Diversity Method
2 Alpha Diversity and Richness 1,2 Beta Diversity Method Beta Diversity
Andoh 2016 [17] O vs. L Shannon index Significantly lower in O (2.40 ± 0.17) vs. L (2.80 ± 0.14)p < 0.01 PCA
3 PCA 3 at phylum level showed different




BMI Shannon index Significantly lower in high vs. low BMI (p = 0.0001) — —
Borges 2018 [38] — — — — —
Borgo 2018 [18] O vs. NW Shannon index, observedspecies and Faith’s PD
Significantly lower α-diversity (PD) in O vs. n (p < 0.01).
Shannon index and observed species are not reported by
BMI group
Weighted and unweighted
UniFrac 4 metrics and PCoA 5
Bray–Curtis distances
No separation was obtained between O
and NW subjects (p > 0.05). Significant
separation in LAM 7 samples between
NW and O was observed
Chavez-Carbajal
2019 [19]





Shannon index: no significant difference between groups
O: 6.61 ± 0.36
OMS: 6.56 ± 0.38
NW: 6.32 ± 0.46
O vs. NW (p = 0.17)
OMS vs. NW (p = 0.09)
Simpson index: no significant difference between groups
O: 0.97 ± 0.01
OMS: 0.97 ± 0.01
NW: 0.97 ± 0.02
O vs. NW (p = 0.28)
OMS vs. NW (p = 0.52)
Chao1 index: significantly higher in O vs. NW
O: 787.1 ± 137.8
OMS: 769.4 ± 101.7
NW: 583.5 ± 87.8
OMS vs. NW (p = 0.003)
O vs. NW (p = 0.002)
Unweighted UniFrac 4 analysis,
PCoA 5
For the unweighted, PCoA 4 analysis
clearly grouped the O and OMS
separating them from the NW (ANOSIM
8; p = 0.01). Weighted analysis showed a
similar result (ANOSIM 8, p = 0.01)
Chen 2016 [20] — Shannon index NR by BMI groups
unweighted and weighted
UniFrac 4 distances
NR by BMI groups
Davis 2016 [40] O vs. OW vs.NW
Simpson’s Index of Diversity,
Chao1, Shannon index
Effective Number of Species
Shannon index Effective Number of Species: No significant
differences reported
O: 228.2 ± 134.1
OW: 218.1 ± 134.2
NW: 179.9 ± 103.1
p = not reported
Chao1 and Simpson’s Index NR
— —





Groups 1 Alpha Diversity Method
2 Alpha Diversity and Richness 1,2 Beta Diversity Method Beta Diversity
Davis 2020 [39] High FMI vs.Low FMI
Shannon index, Fishers
index, Chao 1, Observed
species
The alpha diversity and richness indices were lower in the
high versus low FMI 1 group:
Shannon index: no significant differences (data not shown)
Fisher index: no significant differences (MD −6.2,
95%CI −12.7, 0.4; p = 0.065).
Chao1 index: significantly lower in high vs. low FMI
(MD −46.1, 95%CI −90.2, −2.0; p = 0.040);
Observed species: significantly lower in high vs. low FMI





O vs. OW vs. L Shannon index and numberof observed OTUs
Shannon index: significant differences
(lower in O/OW vs. L)
O: 3.1 ± 0.7
OW: 3.0 ± 0.7
L: 3.2 ± 0.7
p = 0.04
# observed OTUs: significant differences
(lower in O/OW vs. L)
O: 142.5 ± 36.4






NR by BMI groups
Fei 2019 [43] O vs. OW vs. L Shannon index, Chao1diversity, observed OTUs NR by BMI groups Beta diversity (PERMANOVA
6) NR by BMI groups
Finucane
2014 [44] O vs. L
Shannon index, observed
OTUs
Shannon index: No differences in O vs. L
Richness (total number of OTUs): No difference in O vs. L — —
Gallè 2020 [45] O/OW vs.NW/UW Shannon index
No significant differences in O/OW (2.5 ± 0.2) vs. NW/UW
(2.5 ± 0.2)
p = 0.77
PCoA 5 using the METAGEN
assist platform
ANOSIM 8 test yielded no significant
dissimilarity for the BMI groups
(R = −0.011, p = 0.5)
Gao 2018 [46] O vs. NW Shannon, Simpson, Numberof observed OTUs
Shannon index: Significantly lower in O vs. NW (p < 0.01)
Simpson index: Significantly lower in O vs. NW (p < 0.001)
# observed OTUs: No significant difference in O vs. NW
PCoA 5 of samples by weighted
and unweighted UniFrac 4
distance
Fecal microbial communities of the four
BMI groups were not distinct from each




O vs. OW vs.
NW vs. UW Shannon index No difference between UW, NW, OW and O individuals — —
Kaplan 2019 [48] NW vs. OW vs.O (class I, II, III) Shannon index
Significantly lower in O Class III vs. NW: Beta (95% CI)
NW Ref.
OW −0.01 (−0.08, 0.10)
O Class I −0.08 (−0.18, 0.01)
O Class II −0.09 (−0.21, 0.03)
O Class III −0.19 (−0.35, −0.03)
Bray-Curtis distances NR by BMI groups





Groups 1 Alpha Diversity Method
2 Alpha Diversity and Richness 1,2 Beta Diversity Method Beta Diversity
Kasai 2015 [21] O vs. L Shannon index Significantly higher in O vs. Lp < 0.05 PCA








(PD), and number of
observed sequence variants
Shannon index, PD and number of observed sequence
variants: No significant differences across groups.
Bray–Curtis and unweighted
UniFrac 4; PCoA 5
Being O compared with normal BMI at
age 46 was statistically significantly
associated with Bray–Curtis, unweighted
Uni-Frac, and weighted UniFrac
distances (all p values ≤ 0.001); whereas
OW BMI and BMI history were not
statistically significantly associated with
the beta diversity matrices
Oduaran
2020 [34] O vs. L Shannon index, Chao1
Shannon diversity in Bushbuckridge: No significant
differences in O (4.56 ± 0.39) vs.
L (4.49 ± 0.53 (4.56 ± 0.41 after exclusion of an outlier))
p = 0.85
Chao 1: Significantly higher in O vs. L (p = 0.001)
Shannon diversity in Soweto: No significant differences in
O (4.30 ± 0.56) vs. L (4.49 ± 0.34)
p = 0.45
Chao 1: No significant differences in O vs. L (p = 0.33)
Bray-Curtis distances, PcoA 4,5
Beta diversity measurements showed
statistically significant differences
between the lean and obese groups in
Bushbuckridge with calculated
Bray-Curtis distances using the
permutational analysis of variance
(PERMANOVA 6) test (p = 0.02 for
Bushbuckridge and p = 0.84 for Soweto)










number of observed OTUs
Shannon index: Significant decrease across BMI tertiles
tertile 1: 4.6 ± 0.5
tertile 2: 4.5 ± 0.5
tertile 3: 4.4 ± 0.5
p < 0.01
Chao1: Significant decrease across BMI tertiles
tertile 1: 10,848 ± 3916
tertile 2: 9761 ± 3006
tertile 3: 9162 ± 3590
p = 0.02
# observed OTUs: Non-significant decrease across BMI tertiles
tertile 1: 3613 ± 1462
tertile 2: 3160 ± 999
tertile 3: 3093 ± 1317
p = 0.07
Unweighted UniFrac 4, weighted
UniFrac 4, and Bray-Curtis
distances
NR by BMI groups
Ozato 2019 [32] High VFA vs.Low VFA Shannon index
Significantly lower in High vs. Low VFA in men (p = 0.053)
Non-significantly higher in High vs. Low VFA in women
(p >0.05)
— —





Groups 1 Alpha Diversity Method
2 Alpha Diversity and Richness 1,2 Beta Diversity Method Beta Diversity
Patil 2012 [52] O vs. NW Shannon index and Simpsonindex
Shannon index: No significant differences reported
O: 2.89 ± 0.56
NW: 2.84 ± 0.75
p = not reported
Simpson index: No significant differences reported
O: 0.11 ± 0.08
NW: 0.14 ± 0.18
p = not reported
UniFrac 4 analysis
Library cluster analysis clearly
demonstrates clustering of lean and
normal libraries except L3 (which has an
unusually high Bacteroides genus counts).
Interestingly, libraries O1 and O2 cluster
in the normal/lean clade
Peters 2018 [33] O vs. NW Shannon index, Richness,and Evenness
Shannon index: Non-significantly lower in O vs. NW
(beta = −0.11, p = 0.11, pHolm = 0.22)
Evenness: Non-significantly lower in O vs. NW (beta = −0.01,
p = 0.22, pHolm = 0.44).
Richness (i.e., number of OTUs): Significantly lower in O vs.
NW (beta = −9.87, p = 0.04, pHolm = 0.08);
Significantly lower richness in O vs. NW in women (p = 0.03),
but not in men (p = 0.47)
Weighted UniFrac4 distance,
PCoA 5
Partial constrained analysis of PCoA 4 of
the weighted UniFrac distance revealed
separation of obese from both
healthy-weight and OW participants on
the main axis, with OW separated from
healthy-weight participants on the
secondary axis, although PCoA 4 did not
reveal clustering by BMI category. In
PERMANOVA 6 analysis of the weighted
UniFrac distance, BMI category was not
associated globally with overall
microbiome composition (p = 0.14). In
pairwise comparisons, overall
microbiome composition differed
between O and HW participants (p = 0.04,
pHolm = 0.07), while OW and HW
participants did not differ significantly




OW vs. L Shannon index No significant difference in OW (4.66) vs. L (4.92)p = 0.18 Weighted UniFrac
4 distances
PCoA 5 plots failed to reveal any
difference in between the L and OW
groups (data not shown)
Salah 2019 [54] O vs. OD vs.NW
Shannon index, Number of
OTUs
Shannon index: Significantly lower in O vs. NW (p < 0.01)
Significantly higher in OD vs. NW (p < 0.05)-
Number of OTUs: NR
PCoA 5 unweighted and
weighted UniFrac 4 distance
matrix
PCoA 5 plot based on unweighted
Uni-Frac was built and showed
significant BMI and diabetes-dependent
clustering of samples (PERMANOVA 6;
p = 0.001)





Groups 1 Alpha Diversity Method
2 Alpha Diversity and Richness 1,2 Beta Diversity Method Beta Diversity
Thingholm
2019 [55] O vs. L
PD calculated using the
phylogenetic tree built on the
aligned OTU sequences
PD significantly lower in O vs. L (p = 3.20310−11 by
robust regression).
Function betadisper from the R
package vegan with default
settings to evaluate dispersion
between groups
Composition (beta-diversity) of
taxonomic and functional profiles (adonis
q < 0.1), and taxonomic evaluation of
dispersion (genera, betadisper q < 0.1)
significantly lower in O vs. L, although
not for functional features (betadispersion
q > 0.1)
Verdam
2013 [56] O vs. NO
Simpson’s reciprocal index of
diversity (1/D)
Significantly lower in O (128.7 ± 33.2) vs.






calculated using phyloseq NR by BMI groups
PCoA 5 using Bray–Curtis
dissimilarity with Hellinger
transformation
NR by BMI groups
Whisner
2018 [58] —
PD metrics calculated by
QIIME via Faith’s PD NR by BMI groups
PCoA 5 using weighted and
unweighted UniFrac 4 distances
NR by BMI groups
Wilkins
2019 [59] — — —
Weighted UniFrac 4
beta-diversity
NR by BMI groups




Shannon Index, Chao Index, and Number of OTUs reported at
OTU cutoffs of 3, 6 and 9 distance units
France
O significantly lower diversity and richness than NW at all the
OTU cutoffs (p < 0.05).
Saudi Arabia
No significant difference in diversity and richness between O
and NW at all the OTU cutoffs
PCoA 5 calculated in QIIME by
choosing Bray–Curtis distance
methods at the genus level
PCoA 5 showed that O and NW
individuals clustered independently.
NW individuals from France and Saudi
Arabia clustered together, but O Saudis
clustered independently from obese
French
Yun 2017 [60] O vs. OW vs.NW
PD metrics calculated by
QIIME 9
Significantly lower diversity (PD) in O vs. NW (p < 0.01) and
OW vs. NW (p < 0.01) PCoA
5 of weighted UniFrac 4
Weighted UniFrac 4 PCoA 5 identified
significant differences between groups
(ANOSIM 8; R = 0.020, p = 0.001)
1 L: Lean; NO: non-obese; NW: Normal weight; OW: Overweight; O: Obese; OD: obese diabetic; OMS: Obese and metabolic syndrome; UW: underweight; VFA: visceral fat area; FMI: fat
mass index; 2 PD: phylogenetic distance; OTUs: operational taxonomic units; 3 PCA: Principal component analysis; 4 UniFrac: unique fraction metric; 5 PCoA: Principal Coordinates
analysis; 6 PERMANOVA: permutational multivariate analysis of variance 7 LAM: lumen-associated microbiota; 8 ANOSIM: Analysis of Similarities; 9 QIIME: Quantitative Insights Into
Microbial Ecology. NR: not reported.
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The Simpson index, reported in four studies, was found to be significantly lower in
obese compared to non-obese persons in two studies [46,56] and to be non-significantly
different in two studies [19,52]. Another four studies used the phylogenetic distance (PD)
between samples to assess diversity and it was found to be significantly lower in obese
than non-obese persons in three studies [18,55,60] and non-significant in one study [49].
The Chao1 estimator for richness, reported in seven studies, was found to be lower
in obese compared to non-obese persons in three studies [35,39,51], and higher in obese
persons in two studies [19,34], and non-significant in two studies for the populations of
Saudi Arabia [35] and Soweto [34]. The number of observed species/OTUs, reported
in nine studies, was found to be lower in obese compared to non-obese persons in four
studies [33,35,39,41], and non-significantly different in five studies [35,44,46,49,51]. Pe-
ters et al. [33] observed significantly lower richness in obese versus non-obese women
(p = 0.03), but not in men (p = 0.47), and Yasir et al. [35] found a significantly lower number
of OTUs among obese as compared to non-obese persons only among the French, but no
significant differences in richness between obese and non-obese persons among the Saudis
(Figure 3). One study [40] used a Shannon index Effective Number of Species to measure
richness and found no significant differences between obese and non-obese persons.
Of the 22 studies that used the Shannon Index as an alpha diversity measure to
compare obese and non-obese persons, only seven studies provided sufficient information
for meta-analysis. The forest plot (Figure 4) showed that differences in microbial diversity
between obese and non-obese persons, as assessed by the Shannon index, did not reach
statistical significance. Given the substantial heterogeneity, we conducted sensitivity
analysis by omitting one study at a time. These analyses suggested that one study from
Japan (DB-BA 9.0 taxonomic reference database used), which observed a significantly lower
Shannon Index in obese versus non-obese persons, contributed the most to heterogeneity
in the meta-analysis on the Shannon index [17]. However, when we excluded this study
from the analyses, the mean difference between obese and non-obese persons changed
direction, but remained statistically non-significant (MD 0.01, 95%CI −0.11, 0.13, I2 = 43%,
n = 6 studies, Supplement Figure S2).
Figure 4. Forest plot of the differences in alpha diversity between obese and non-obese persons
by Shannon index. Study references: Andoh et al. [17], Chavez-Carvajal et al. [19], De la Cuesta—
Zuluaga et al. [41], Gallè et al. [45], Oduaran et al. [34], and Patil et al. [52].
A total of 24 studies assessed beta diversity, although nine studies did not report beta
diversity by BMI. Eleven studies [17,19,21,33–35,49,52,54,55,60] found microbial dissimilar-
ities across the BMI groups, whereas only four studies did not find any [18,45,46,53].
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3.2.2. Differences in The Microbial Composition
At the Phylum Level
Differences in the relative abundance of the gut microbial composition at the phylum
level between obese and non-obese persons are depicted in Table 3.
At the individual study level, regarding Firmicutes, out of 17 studies, 11 studies
did not observe statistically significant differences in their relative abundance between
obese and non-obese persons [18,20,21,33,34,41,44–46,52,54], whereas six studies observed
significantly higher proportions in the relative abundance in the obese group compared to
the non-obese group [17,19,32,35,53,56] (Table 3 and Figure 5). The study of Yasir et al. [35]
found significantly higher relative abundance of Firmicutes in the obese group compared
to the non-obese only in the sample from Saudi Arabia (men only) but not in the French
study arm (men and women). Interestingly, Ozato et al. [32] found higher proportions of
Firmicutes in women with a higher BMI (p for trend: 0.004) but not in men. Differences
in the relative abundance of Bacteroidetes showed contradictory results (Table 3). Out of
18 studies, 10 studies did not observe statistically significant differences between obese and
non-obese persons [17–20,33,44,45,52–54], four studies found a higher relative abundance of
Bacteroidetes in obese persons compared to non-obese persons [34,35,46,49], whereas four
studies found lower relative abundance of Bacteroidetes among obese persons compared to
non-obese persons [21,32,41,56] (Figure 3). The study of Ozato et al. [32] found a significant
decrease in the relative abundance of the Bacteroidetes phylum across BMI groups in
women (p for trend: <0.001) but not in men. The study of Yasir et al. [35] found significantly
higher proportions in the relative abundance of Bacteroidetes in French obese persons
compared to their non-obese counterparts (including both men and women). Differences in
the relative abundance between obese and non-obese persons for the phyla of Firmicutes
and Bacteroidetes are also depicted in Figure 5. Study-level meta-analyses could only be
performed for the phyla of Firmicutes and Bacteroidetes in six studies (Figure 6). Sensitivity
analysis were performed by omitting one study at a time, but the heterogeneity was still
substantial (I2 > 70%).
Figure 5. Number of studies that reported differences in the relative abundance of phyla as signif-
icantly higher (grey), lower (diagonal stripes) or not different (dotted) when comparing obese to
non-obese persons.
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Figure 6. Forest plot of the differences in the gut microbiome composition at phylum level be-
tween obese and non-obese. Study references: Andoh et al. [17], Borgo et al. [18], De la Cuesta—
Zuluaga et al. [41], Gallè et al. [45], Rahat—Rozenbloom et al. [53], and Verdam et al. [56].
The forest plot showed a statistically significant higher relative abundance of Firmi-
cutes in obese compared to non-obese persons (MD 5.50 [95%CI 0.27, 10.73]; I2 = 87%, n = 6)
but non-significantly lower Bacteroidetes (MD −4.79 [95%CI −10.77, 1.20]; I2 = 86%, n = 6)
(Figure 4).
Ten studies reported data on the F:B ratio, although meta-analysis could only be
conducted in two studies. Three studies reported data on the B:F ratio and meta-analysis
could be performed in two of the three studies (Table 3). The results were controversial:
four studies reported significant differences between obese and non-obese persons (higher
F:B ratio in obese than in non-obese persons) [19,21,48,53], while six studies reported no
significant differences [33,45,49,54,58,60]. In the meta-analysis, we found a statistically non-
significantly higher F:B ratio in obese versus non-obese persons (MD 0.43 [95%CI −0.25,
1.12]; I2 = 66%, n = 2). Regarding the B:F ratio, two studies reported significant differences
between obese and non-obese persons (B:F ratio lower in obese than in non-obese) [41,56],
while one study reported no significant differences in the B:F ratio [17]. In the meta-analysis,
a statistically significantly lower B:F ratio in obese versus non-obese persons (MD −0.08
[95%CI −0.16, −0.00]; I2 = 0%, n = 2) was observed (Figure 7).
Figure 7. Forest plot of the differences in the Firmicutes to Bacteroidetes ratio between obese and
non-obese. Study references: Andoh et al. [17], De la Cuesta—Zuluaga et al. [41], Gallè et al. [45], and
Kasai et al. [21].
Nutrients 2022, 14, 12 30 of 41
Differences in the relative abundance between obese and non-obese persons for the
phyla of Actinobacteria (n = 11 studies), Fusobacterium (n = 8), Proteobacteria (n = 12) and
Verrucomicrobia (n = 4) are depicted in Table 3 and Figure 5. Regarding Actinobacteria
(n = 11), none of the studies found differences between the groups, with the exception of
one study that found a higher abundance of Actinobacteria in obese persons compared to
the rest of the groups (normal weight, diabetes, and obese with diabetes) (p = 0.04) [54].
Regarding the phylum Fusobacteria (n = 8), five studies found no differences in their relative
abundance between obese and none obese persons [19–21,34,54], whereas two found a
higher proportion [17,46], and one found a lower proportion of Fusobacteria in obese
persons compared to the non-obese [47]. Regarding the phylum of Proteobacteria (n = 12),
eight studies did not observe statistically significant differences between obese and non-
obese persons [17–19,21,32,34,44,52], three found higher proportions of Proteobacteria in
obese persons [35,46,56], and one found lower proportions [54]. The study of Yasir et al. [35]
found significantly higher proportions in the relative abundance of Proteobacteria in French
obese persons compared to their non-obese counterparts (including both men and women),
whereas no significant differences were observed in Saudi obese persons compared to their
non-obese counterpart (men only). Regarding the phylum Verrucomicrobia (n = 4), three
studies found no differences in their relative abundance between obese and non-obese
persons [18,34,35], whereas one study found a higher proportion of Verrucomicrobia in
obese compared to non-obese persons [54].
At the Genus Level
A total of 27 studies reported data on the relative abundance between obese and
non-obese persons at the genus level. A list of bacteria found to be statistically significantly
higher or lower in obese compared to non-obese persons is depicted in Table 4.
Table 4. Significant differences in the relative abundance of bacteria at genus level between obese
and non-obese persons.
Genus (#Studies) Significantly Higher in Obese Significantly Lower in Obese
n [Citations] n [Citations]
Firmicutes
Acetanaerobacterium 1 1 [34] — —
Acidaminococcus 3 [32,48,51] — —
Anaerococcus 2 [17,59] — —
Anaerotruncus 1 [45] 1 [48]
Blautia 4 [20,33,49,50] 1 [32]
Butyrivibrio 1 — 1 [54]
Catenibacterium 2 [34,48] — —
Clostridium 2 1 [54] 1 [35]
Clostridium_IV 1 1 [34] — —
Clostridium_XIVa 3 1 [34] — —
Clostridium_XIVb 3 1 [34] — —
Coprobacillus — 1 [48]
Coproccocus 3 [17,19,59] 1 [33]
Dehalobacterium — 1 [33]
Dialister 2 [18,19] — —
Dorea 4 5 [20,35,43,45,49] — —
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Table 4. Cont.
Genus (#Studies) Significantly Higher in Obese Significantly Lower in Obese
n [Citations] n [Citations]
Eubacterium 2 [20,45] — —
Faecalibacterium 2 2 [19,54] 2 [17,35]
Finegoldia — — 1 [17]
Fusicatenibacter 3 — — 1 [34]
Gemella 1 [45] — —
Intestinimonas 1 [34] — —
Lachnoanaerobaculum — — 1 [17]
Lachnobacterium 1 [45] — —
Lachnospira 1 [19] — —
Lactobacillus 2 1 [35] — —
Megasphera 2 [43,48] — —
Oscillibacter 3 1 [34] 1 [55]
Oscillospira 1 [37] 4 [18,33,48,51]
Parvimonas 1 [17] — —
Phascolarctobacterium 1 1 [34] — —
Roseburia 4 [19,43,49,54] — —
Ruminoccocus 3 4 [34,37,41,49] 2 [48,54]
Sporobacter 3 1 [34] — —
Staphylococcus 1 [54] — —
Streptococcus 3 5 [33,34,43,45,48] — —
Subdoligranulum — — 1 [17]
Bacteroidetes
Alistipes 1 2 [17,34] 1 [55]
Bacteroides 2 3 [35,52,59] 2 [17,19]
Parabacteroides 1,3 2 [34,43] 1 1 [34] 3
Paraprevotella — — 1 [45]
Prevotella 3 [34,48,54] — —
Actinobacteria
Bifidobacterium — — 1 [32]
Corynebacterium 1 [59] — —
Eggerthella 5 — — 2 [48,60]
Olsenella — — 1 [17]
Rothia 1 [59] — —
Fusobacteria
Fusobacterium 2 [17,46] — —
Sneathia 1 [45] — —
Proteobacteria
Desulfovibrio 1 [43] 1 [17]
Escherichia-Shigella 2,3 2 [34,35] — —
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Table 4. Cont.
Genus (#Studies) Significantly Higher in Obese Significantly Lower in Obese
n [Citations] n [Citations]
Haemophilus 3 1 [34] — —
Jannaschia 1 [45] — —
Oxalobacter 3 1 [34] — —
Paucibacter 1 [45] — —
Succinivibrio 1 [45] — —
Sutterella 1 2 [34,46] — —
Verrucomicrobia
Akkermansia 1 1 [34] 2 [54,55]
Synergistetes
Cloacibacillus — — 1 [48]
Euryarchaeota
Methanobrevibacter — — 1 [50]
Lentisphaerae
Victivallis 3 — — 1 [34]
1 Ref. [43]: in Bushbuckridge; 2 Ref. [57]: in France; 3 Ref. [43]: in Soweto; 4 Ref. [57]: in Saudi Arabia; 5 Ref. [56]:
no longer significant after adjustment for carbohydrate.
Significantly higher in obese
Thirteen genera, namely, Acidaminococcus, Anaerococcus, Catenibacterium, Dialister,
Dorea, Escherichia-Shigella, Eubacterium, Fusobacterium, Megasphera, Prevotella, Rose-
buria, Streptococcus, and Sutterella were found to be significantly more abundant among
obese persons than among the non-obese in at least two studies.
Significantly lower in obese
Bifidobacterium and Eggerthella were found to be significantly less abundant among
obese persons than among the non-obese in at least two studies.
Controversial findings
Discrepant results were found in 13 genera of the bacteria Akkermansia, Alistipes,
Anaerotruncus, Bacteroides, Blautia, Clostridium, Coproccocus, Desulfovibrio, Faecalibac-
terium, Oscillibacter, Oscillospira, Parabacteroides, and Ruminoccocus where they have
been found in higher relative abundance in obese persons in some studies and in lower
relative abundance in others, compared to non-obese persons (Table 4).
Fungi
Only two studies investigated differences in the mycobiota composition between
obese and non-obese persons. The study of Borges et al. [38] found that Penicillium sp.,
Paecilomyces sp., and Fonsecaea sp. fungi separated the obese group from the other groups
(overweight and normal weight). A slightly higher diversity was found in normal weight
persons, and Syncephalastrum sp. (Zygomycota), which was found only in normal weight
persons. Paecilomyces sp. was predominant in normal weight and overweight persons,
whereas Penicillium sp. was the most frequently identified fungi in the obese group.
Furthermore, obese persons displayed higher yeast counts. Whilst Trichosporon sp. was the
most prevalent yeast in normal weight persons, Rhodotorula was increased in overweight
and obese persons. The study of Kaplan et al. [48] failed to find fungal correlates of obesity,
with only Debaryomyces achieving a nominal p value < 0.05.
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3.3. Secondary Outcomes
Microbial Taxonomic Signatures Associated with Obesity
Only two studies explicitly assessed taxonomic signatures associated with obesity [33,44].
In the Peters study [33], a microbiome-based machine learning model accurately classified
obese persons and thus revealed an emerging taxonomic signature of obesity. Obesity
was characterized by a higher abundance of class Bacilli and its families Streptococcaceae
and Lactobacillaceae, and a lower abundance of several groups within the class Clostridia,
including Christensenellaceae, Clostridiaceae, and Dehalobacteriaceae (q < 0.05). Their
findings were consistent across two independent study populations. However, the Finucane
study [44] concluded that there is no simple taxonomic signature of obesity in the microbiota
of the human gut, since they found a large variability between studies (Human Microbiome
Project (HMP) and MetaHIT) in the taxonomic composition of stool microbiomes that did
not allow differences to be evident between lean and obese persons within studies and
even across individuals.
One study [56] classified obese and non-obese persons in two separate clusters, where
15/19 of the obese were classified in cluster 1 and all non-obese were fitted in cluster 2.
The obese cluster showed reduced bacterial diversity compared to the non-obese cluster, a
decreased B:F ratio, and an increased abundance of Proteobacteria. Moreover, in the obese
microbiota cluster, Clostridium cluster IV and XIVa of the Firmicutes phylum were more
abundantly present whereas Bacteroidetes phylum was less abundant.
Another study assessed enterotypes in obese persons and found that the Bact2 en-
terotype, which is characterized by a high proportion of Bacteroides, a low proportion of
Faecalibacterium and low microbial cell densities, is more common in obese (17.7%) com-
pared to non-obese persons (lean or overweight, 3.90%). However, obese persons who
received statin treatment had a lower Bact2 prevalence (5.88%) [57].
3.4. Quality Assessment
A serious risk of bias was mainly found in the first two domains: confounding
(n = 18), because studies did not adjust for potential confounders, and the selection of
participants (n = 12), because nine studies recruited volunteers [17,19,35,37,45–47,52,58],
two studies recruited participants through advertisement [53,56], and one study did not
provide enough information on the recruitment process [54]. Of those studies of moderate
risk for confounding, two studies did not adjust for variables but stratified results or
excluded patients to minimize confounding [34,46], and 12 adjusted mainly for age and/or
sex [20,32,33,37,43,45,48,49,51,53,55,60]. Other variables used for adjustment were dietary
factors (e.g., intake of carbohydrates, vegetables excluding potatoes, intake of whole
fruit, intake of whole grains) [33,48,53,55,60], batch effect [20], country [43], smoking
status [49], BMI [48,49,55], study center [33,48], moderate-to-vigorous physical activity
(MVPA) [48], diabetes [48], heath status [55], polyp status [33], visits returning to home
country [48], education and income [48], and medications, including use of antibiotics and
metformin [48]. Of the 32 studies, 11 were deemed as having an overall moderate risk of
bias and 21 as having an overall serious risk of bias. In general, the meta-analyzed studies
had a serious risk of bias (Table 1, Supplement Table S3).
4. Discussion
In the present systematic review, we found discrepant results on gut microbiome
composition in obese versus non-obese persons across the studies. Statistically significant
lower alpha diversity in obese versus non-obese persons was observed in a substantial
proportion of studies, i.e., less than half for the Shannon index (nine out of 22 studies), half
for the Simpson index (two out of four studies) and number of observed species/OTUs
(four out of eight), and more than half for phylogenic distance (three out of four), and
Chao1 (three out of five). No significant differences in obese versus non-obese persons were
observed in meta-analysis of seven studies for the Shannon index. Microbial dissimilarities
(beta diversity) were observed among BMI categories in the majority of the included studies.
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Observed differences in the gut microbiome composition at the phylum level in obese
versus non-obese persons also showed discrepancies across studies. Firmicutes were found
to be significantly higher in obese versus non-obese persons in six out of seventeen studies,
whereas Bacteroidetes were found to be significantly lower in obese persons in four out of
eighteen studies, but also significantly higher in four other studies. In the meta-analyses
of six studies, Firmicutes were significantly higher and Bacteroidetes non-significantly
lower in obese versus non-obese persons. The Firmicutes to Bacteroidetes ratio was found
to be significantly higher in the obese in four out of ten studies, and the Bacteroidetes to
Firmicutes ratio was found to be significantly lower in the obese in two out of three studies.
The Bacteroidetes to Firmicutes ratio was statistically significantly lower in the obese versus
non-obese in the meta-analysis of two studies, and a non-significantly higher Firmicutes to
Bacteroidetes ratio was observed in the meta-analysis of two further studies. At the genus
level, lower relative proportions of Bifidobacterium and Eggerthella were found in obese
versus non-obese persons, whereas Acidaminococcus, Anaerococcus, Catenibacterium, Dialister,
Dorea, Escherichia-Shigella, Eubacterium, Fusobacterium, Megasphera, Prevotella, Roseburia, and
Streptococcus, and Sutterella were found to be higher in obese versus non-obese persons.
Our investigation shows no significant differences in the Shannon index between
the obese and the non-obese in the meta-analysis, although in the qualitative synthesis a
substantial proportion of studies showed statistically significantly lower alpha diversity
in obese versus non-obese persons, and microbial dissimilarities (beta diversity) were
observed among the BMI categories in the majority of the included studies, confirming that
the microbial population abundances in the gut of obese and non-obese groups were distinct
from each other. One previous meta-analysis [61] that included five studies using high-
throughput technologies in the 16S rRNA gene and that were processed using a common
computational pipeline, also showed a lack of a consistent alpha diversity trend (assessed
by the Shannon index and number of observed species), likely due to the small effect
size observed in studies investigating obesity compared to the larger effect size observed
in studies on inflammatory bowel disease. Another previous meta-analysis [62] that re-
analyzed the studies included in the Walters study [61] and added five more studies that
included BMI and 16S rRNA gene sequence data found similar results to our observations.
Only in two out of ten studies was there a significantly lower diversity in obese versus
non-obese persons observed, whereas the rest showed similar trends—although these were
non-significant. However, after applying a random-effects linear model to combine the
studies, they found a statistically significantly lower richness, evenness, and diversity
among obese persons (Shannon diversity index, observed richness, and Shannon evenness),
despite the small effect size [62].
In the present systematic review, we found evidence that the composition of the gut
microbiome of obese persons differs from the non-obese both at the phylum and genus
level. In the qualitative synthesis at the phylum level, although the majority of the studies
did not observe statistically significant differences in the relative abundance of the Gram-
positive Firmicutes and Gram-negative Bacteroidetes between the obese and non-obese, a
substantial proportion of studies observed statistically significantly higher Firmicutes (six
out of seventeen) and lower Bacteroidetes (four out of eighteen) in obese versus non-obese
persons. In the quantitative analysis, Firmicutes were significantly higher in the obese
compared to the non-obese, whereas for Bacteroidetes non-significantly lower relative
abundances were found. In both meta-analyses, significant heterogeneity was observed.
In the qualitative synthesis at the phylum level, a statistically significantly higher F:B
ratio and a lower B:F ratio was observed in obese persons compared to non-obese persons
in a substantial number of studies, and a significantly lower B:F ratio was observed in
the meta-analysis (two studies), whereas the F:B ratio was non-significantly higher (two
further studies). Thus, no clear significant differences between the F:B or B:F ratio and
obesity status was found. In animal studies, the F:B ratio is considered a hallmark of obesity
and is therefore used as an outcome to assess the effects of many anti-obesity dietary
supplements [63,64] based on their capacity to modulate the gut microbiome by reducing
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the F:B ratio in the obese. Two systematic reviews [24,25] that included studies measuring
the ratio by high-throughput sequencing methods and other methods, such as culture,
flow cytometry, and qPCR, among others, found more studies that showed no statistically
significant differences in the F:B ratio between obese and non-obese persons than others
that did, which is in agreement with our findings.
Mechanistic explanations why Bacteroidetes and Firmicutes may be found at differ-
ential proportions in obese versus non-obese persons may be provided by studies investi-
gating the host-gut microbiota relationship by relating the gut microbiome composition
to circulating metabolites [50]. For example, short-chain fatty acids (SCFAs) are formed
during the bacterial fermentation of carbohydrates in the colon, with acetate being the
most common one found in the human colon, followed by butyrate and propionate [52,53].
A positive correlation between Firmicutes and fecal SCFA has been observed [53], which
supports the hypothesis that obese persons have a distinct microbial profile that is more
efficient in fermenting substrates and in producing higher fecal SCFA concentrations than
that of their lean counterparts [52,53]. Whilst members of the Bacteroidetes phylum are
acetate and propionate producers, bacteria belonging to the phylum of Firmicutes are
mainly butyrate producers [65]. In animal studies acetate produced by the microbes is used
as a substrate for the hepatic lipo- and gluconeogenesis, promoting obesity [28]. Diets rich
in fats or carbohydrates favor the increase of Firmicutes and the decrease of Bacteroidetes
both in animals and humans [28], which may also play a role in the differences in gut mi-
crobiome. However, dietary intake was considered only in a minority of the here included
studies [33,48,53,55,60].
In the qualitative synthesis at the genus level, lower relative proportions of Bifidobac-
terium and Eggerthella (Actinobacteria phylum) were found in the obese group compared
to the non-obese, whereas the genera of Acidaminococcus, Anaerococcus, Catenibacterium,
Dialister, Dorea, Eubacterium, Megasphera, Roseburia, Streptococcus (Firmicutes phylum), Fu-
sobacterium (Fusobacteria phylum), Prevotella (Bacteroidetes phylum), Escherichia-Shigella,
and Sutterella (Proteobacteria phylum) were found to be significantly higher in the obese.
The genera of Sutterella and Catenibacterium have been previously associated with obesity
in children and adolescents [66] and pregnant women [67]. Fusobacterium and Megasphera
produce butyrate from glutamate and lysine amino acids releasing harmful by-products like
ammonia, which can have deleterious effects upon the host [65,68]. Discrepant results were
found for the genera of Akkermansia (Verrucomicrobia phylum), Desulfovibrio (Proteobacte-
ria phylum), Alistipes, Parabacteroides, Bacteroides (Bacteroidetes phylum), Anaerotruncus,
Blautia, Clostridium, Coproccocus, Faecalibacterium, Oscillibacter, Oscillospira and Ruminoccocus
(Firmicutes phylum). These findings highlight the complexity of the microbial ecosystem
of the gut and suggest that a greater relative abundance of the phylum Firmicutes and a
lower relative abundance of Bacteroidetes in the obese do not necessarily translate into a
common pattern of all genera belonging to these phyla, since several genera from the same
phylum may be found in higher or in lower proportions in obese persons. For example,
the Firmicutes genus Oscillospira was found to be significantly lower in obese compared
to non-obese persons in four studies (and significantly higher in one study), which is in
contrast to the hypothesis that obese gut microbiome is enriched in Firmicutes, that is also
supported by our qualitative and quantitative analyses at the phylum level. One previous
study meta-analyzing data from individuals with different health statuses found very few
consistent genus-level associations between lean and obese persons [69]. For example, in
agreement with our findings, they found that Roseburia was significantly enriched in obese
persons [69]. Another previous meta-analysis found that, in agreement with our findings,
Bifidobacterium was depleted in obese persons, whereas Eubacterium rectale, and Roseburia
intestinalis were enriched in obese persons [61]. However, they found that Bacteroides
were higher in obese whereas Alistipes, and Oscillospira were lower in obese compared to
non-obese persons [61]. Oscillospira which has been found associated with leanness and
health [70], has also been found to be enriched in metabolically healthy obese persons
compared to metabolically unhealthy obese persons [6], likely due to their capability of
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producing high SCFA concentrations, like propionate and butyrate, which have beneficial
effects on body weight control, inflammatory status, and insulin sensitivity [6,71]. We
found no sufficient evidence of a specific taxonomic signature associated with obesity in
the few studies addressing this question.
Overall, discrepancies found for each outcome when comparing obese with non-obese
persons may be explained by factors such as sex and geographical differences, which may
also reflect differences in their dietary habits. For example, Yasir et al. [35] compared
the gut microbiome of obese and non-obese persons in France and Saudi Arabia with
discrepant results, which may be likely due to, on the one hand, sex-differences, given
that the French study population included both men and women whereas the Saudi
population included only men, and, on the other hand, geographical differences in diet [35].
A large amount of study-specific variation can likely be attributed to differences in DNA
isolation, sequencing and bioinformatic processing. Several studies have demonstrated that
methodological differences can yield substantial variation in the results [72–75]. Our meta-
analysis shows that technical variations may have masked potential biological differences
when comparing across studies. The current method of analysis makes it very hard to make
generic conclusions about the relation between microbiome and health and thereby cannot
yet lead to medical grade interventions. Therefore, standardization and new analysis
techniques are needed. An important factor that only recently has gained attention is the
importance of including absolute counts, e.g., by applying spike-in standards [76] or flow
cytometry based cell counting [77], to overcome the limitations of working with relative
abundances. Additionally, some attempts have been made to unify several reference
databases containing sequences of 16S rRNA genes to improve taxonomic classification [78].
Other factors that may contribute to discrepant findings are differences in the number
and recruitment process of participants, which might preclude the observation of small
differences between groups, as well as lack of adjustment for relevant lifestyle-associated
factors that have an influence in the composition and diversity of the gut microbiome [27,61].
In order to increase the robustness of the available evidence, more individual-level meta-
analyses contributing to the elucidation of the role of the gut microbiome in obesity are
warranted, where the BMI comparison groups can be uniformly defined, and adjustment for
confounders can be done in a comparable fashion covering critical factors influencing the
gut microbiome composition, such as sex, age, diet, physical activity, and the microbiome
data processed in a standardized manner [79].
Strengths and Limitations
This is the first systematic review assessing the differences in the gut microbiome
composition between obese and non-obese persons in a quantitative fashion through meta-
analysis. Furthermore, for better comparability, we only included studies that analyzed
the gut microbiome composition by means of high-throughput sequencing techniques.
Furthermore, we were able to conduct meta-analyses for the two dominant phyla in the gut
microbiome, Firmicutes and Bacteroidetes, although only a third of the included studies
provided sufficient data. Nevertheless, it should be acknowledged that because many
studies could not be included in the meta-analysis due to insufficient availability of data,
our meta-analysis does not necessarily reflect the full available evidence. We conducted
our searches in Pubmed and EMBASE, the two most commonly used databases for search-
ing biomedical literature, although we cannot rule out that we may have missed some
studies given that the search was restricted to the English language. In order to enable
the inclusion of more published studies in meta-analysis, more standardized reporting
is essential. In line with the limited data available for meta-analysis, we were unable to
stratify analysis by country (as a proxy for diet) or sex, two known factors that can greatly
influence the composition of the gut microbiome. Moreover, the definition of obese and
non-obese groups was very heterogeneous, which may lead to an under- or over-estimation
of the observed differences in our meta-analyses. The included studies were conducted in
different countries with distinct eating habits that have an impact on the microbial ecology
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of the human gut microbiome, and were also of observational design, which means that
confounding could have precluded small but significant differences in the composition of
the gut microbiome between obese and non-obese persons. There are other factors, apart
from the aforementioned sex [20,33,45], ethnicity or geographical location [20,34,35,43,48],
and diet [9,41,45,47,53], that have the capacity to influence and therefore modify the compo-
sition of the gut microbiome, such as physical activity [45,58], smoking [47], and changes in
the metabolites produced by gut bacteria [19,50,53,55], among other factors, e.g., fecal cal-
protectin, intestinal permeability [56], or cardiometabolic status [41,42]. These factors may
explain the heterogeneity found among the meta-analyzed studies. However, we were not
able to conduct a meta-regression analysis to examine whether these factors could explain
the variability found in the meta-analyses. Moreover, the majority of the meta-analyzed
studies were judged as having a serious risk of bias, downgrading the value of the level of
evidence provided. Of the eleven meta-analyzed studies, six were not population-based
(participants recruited through advertisements or as volunteers), and ten did not adjust
for covariates.
5. Conclusions
Overall, we observed discrepant findings in the gut microbiome composition of obese
versus non-obese persons across studies both at the phylum and at the genus level. Lower
alpha diversity in obese versus non-obese persons was observed in a substantial proportion
of studies, but our meta-analysis on the Shannon Index yielded no significant differences.
The B:F ratio might be considered as a marker of dysbiosis for obesity, although more
research with standardized technologies is needed to consider it a hallmark of obesity or to
replace it with a more fine-grained measure than comparing communities merely on the
level of phyla. However, caution is required to infer these findings to any population given
that few studies could be meta-analyzed and substantial heterogeneity was found. For the
sake of data accuracy, reproducibility, and comparability of the results, standardization and
harmonization of DNA extraction, amplification methods, high-throughput sequencing
technologies and reference databases for taxonomic classification are needed to allow for
better interoperability between studies, given that extensive omics data require more com-
putational expertise and resources to manage and interpret results. More individual-level
meta-analyses—preferably with standardized bioinformatics pipelines—allowing for more
flexible and standardized approaches than study-level meta-analysis may help to clarify
the here observed discrepant findings. Together with new studies using standardized and
advanced methodologies this would allow for the design of disease prevention strategies,
as well as personalized microbiome-modulating treatment strategies against obesity.
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